PMID- 27307153
OWN - NLM
STAT- MEDLINE
DCOM- 20170413
LR  - 20191210
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 42
IP  - 10
DP  - 2016 Oct
TI  - Diagnostic and prognostic value of serum human epididymis protein 4 in patients 
      with primary fallopian tube carcinoma.
PG  - 1326-1335
LID - 10.1111/jog.13053 [doi]
AB  - AIM: The aim of our study was to assess the levels of human epididymis protein 4 
      (HE4) with the common tumor marker carbohydrate antigen 125 (CA125) in the 
      diagnosis and monitoring of therapy for primary fallopian tube carcinoma (PFTC). 
      METHODS: Serum HE4 and CA125 levels from 82 PFTC patients and 154 patients with 
      benign pelvic masses as the control were measured by Roche 
      electrochemiluminescent immunoassay. HE4 determinations for surgery response and 
      recurrence monitoring were assessed in PFTC patients. RESULTS: Serum HE4 and 
      CA125 concentrations were significantly higher in PFTC patients compared with 
      those seen in patients with benign pelvic masses (P < 0.001). Compared with 
      CA125, HE4 had higher specificity, but lower sensitivity whether at early or 
      advanced stage, and the combination of HE4 + CA125 led to higher sensitivity and 
      specificity. HE4 + CA125 performed significantly better than CA125 or HE4 alone 
      in early stage patients. In early stage the sensitivity was 35.7% for HE4 and 
      64.3% for CA125, while sensitivity for the combination of HE4 and CA125 could 
      reach 71.4%. Furthermore, the two markers were associated with the progression 
      and histology of PFTC. Serum HE4 level was closely correlated with surgical 
      therapy. PFTC patients displayed a greater decline in the level of HE4 compared 
      with CA125 (76.4% vs 55.7%). Combined with CA125, HE4 elevation better predicted 
      recurrence in PFTC patients. CONCLUSIONS: This study indicated that serum HE4 
      levels are closely associated with PFTC and the outcome of surgical therapy and 
      recurrence in Chinese patients.
CI  - (c) 2016 Japan Society of Obstetrics and Gynecology.
FAU - Mi, Dong
AU  - Mi D
AD  - Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and 
      Gynecology, Tianjin, China. mrmidong@aliyun.com.
FAU - Zhang, Yue-Xiang
AU  - Zhang YX
AD  - Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and 
      Gynecology, Tianjin, China.
FAU - Wang, Cheng-Jin
AU  - Wang CJ
AD  - Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and 
      Gynecology, Tianjin, China.
FAU - Feng, Qiang
AU  - Feng Q
AD  - Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and 
      Gynecology, Tianjin, China.
FAU - Qi, Pei
AU  - Qi P
AD  - Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and 
      Gynecology, Tianjin, China.
FAU - Chen, Shu-Qin
AU  - Chen SQ
AD  - Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and 
      Gynecology, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20160616
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (CA-125 Antigen)
RN  - 0 (MUC16 protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Proteins)
RN  - 0 (WAP Four-Disulfide Core Domain Protein 2)
RN  - 0 (WFDC2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - CA-125 Antigen/blood
MH  - Fallopian Tube Neoplasms/*blood/*diagnosis/pathology/surgery
MH  - Female
MH  - Humans
MH  - Membrane Proteins/blood
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Proteins/*metabolism
MH  - ROC Curve
MH  - Treatment Outcome
MH  - WAP Four-Disulfide Core Domain Protein 2
OTO - NOTNLM
OT  - CA125
OT  - biomarker
OT  - human epididymis protein 4
OT  - primary fallopian tube carcinoma
OT  - prognosis
EDAT- 2016/06/17 06:00
MHDA- 2017/04/14 06:00
CRDT- 2016/06/17 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2016/04/09 00:00 [accepted]
PHST- 2016/06/17 06:00 [pubmed]
PHST- 2017/04/14 06:00 [medline]
PHST- 2016/06/17 06:00 [entrez]
AID - 10.1111/jog.13053 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2016 Oct;42(10):1326-1335. doi: 10.1111/jog.13053. Epub 
      2016 Jun 16.